Inhibrx Biosciences, Inc. (INBX)
USD 14.09
(-3.16%)
USD 14.09
(-3.16%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -193.3 Million | -115.3 Million | -80.32 Million | -47.96 Million | -32.07 Million | -23.09 Million |
| Net Income | -241.36 Million | -145.22 Million | -81.76 Million | -76.12 Million | -51.4 Million | -31.02 Million |
| Depreciation & Amortization | 1.19 Million | 1.22 Million | 1.19 Million | 1.01 Million | 1.16 Million | 676 Thousand |
| Deferred income taxes | -1.57 Million | - | -9000.00 | -2.14 Million | 1.08 Million | - |
| Stock-based compensation | 20.69 Million | 17.79 Million | 15.04 Million | 5.02 Million | 3.97 Million | 2.48 Million |
| Change in working capital | 15.34 Million | 3.16 Million | -17.51 Million | 12.69 Million | 3.48 Million | 4.24 Million |
| Other non-cash items | 8.24 Million | 5.08 Million | 2.72 Million | 11.56 Million | 9.61 Million | 522 Thousand |
| Investing Cash Flow | -4.59 Million | -686 Thousand | -809 Thousand | -1.36 Million | -1.81 Million | -1.42 Million |
| Investments in PPE | -4.59 Million | -686 Thousand | -864 Thousand | -1.36 Million | -1.81 Million | -1.42 Million |
| Acquisitions | - | - | 55 Thousand | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 55 Thousand | - | - | - |
| Financing Cash Flow | 201.96 Million | 258.55 Million | 83.76 Million | 166.45 Million | 43.32 Million | 13.15 Million |
| Debt repayment | - | -128.81 Million | -39.99 Million | -5.45 Million | -6.19 Million | -5.68 Million |
| Dividends payments | - | - | - | - | - | -828 Thousand |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 201.96 Million | 127.37 Million | 40.2 Million | 136.85 Million | 11.98 Million | 20.36 Million |
| Other Financing Activities | -355 Thousand | 259.99 Million | 83.55 Million | 35.06 Million | 37.53 Million | 19.67 Million |
| Accounts receivables | -521 Thousand | 130 Thousand | -167 Thousand | 117 Thousand | 491 Thousand | -550 Thousand |
| Accounts payables | 2.1 Million | -705 Thousand | -4.64 Million | 10.42 Million | -3.47 Million | 4.91 Million |
| Inventory | - | - | -11.03 Million | 7.75 Million | -2.47 Million | -672 Thousand |
| Other working capital | 13.76 Million | 3.73 Million | -1.67 Million | -5.6 Million | 8.93 Million | 556 Thousand |
| Cash at beginning of period | 273.86 Million | 131.3 Million | 128.66 Million | 11.54 Million | 2.1 Million | 13.47 Million |
| Cash at end of period | 277.92 Million | 273.86 Million | 131.3 Million | 128.66 Million | 11.54 Million | 2.1 Million |
| Capital Expenditure | -4.59 Million | -686 Thousand | -864 Thousand | -1.36 Million | -1.81 Million | -1.42 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 4.05 Million | 142.56 Million | 2.63 Million | 117.12 Million | 9.43 Million | -11.36 Million |
| Free Cash Flow | -197.9 Million | -115.98 Million | -81.18 Million | -49.33 Million | -33.88 Million | -24.52 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 1.85 Billion | -78.71 Million | -93.6 Million | -241.36 Million | -51.78 Million | -47.05 Million |
| Depreciation & Amortization | 475 Thousand | 360 Thousand | 298 Thousand | 1.19 Million | 304 Thousand | 294 Thousand |
| Deferred income taxes | - | - | -4.56 Million | -1.57 Million | 1000.00 | - |
| Stock-based compensation | 47.52 Million | 5.04 Million | 6.42 Million | 20.69 Million | 6.53 Million | 6.25 Million |
| Change in working capital | 35.49 Million | 7.19 Million | 28.35 Million | 15.34 Million | -10.97 Million | -3.44 Million |
| Other non-cash items | -1.96 Billion | 5.38 Million | 6.26 Million | 8.24 Million | 1.68 Million | 1.65 Million |
| Investing Cash Flow | -1.21 Million | -1.11 Million | -3.44 Million | -4.59 Million | -811 Thousand | -317 Thousand |
| Investments in PPE | -1.21 Million | -1.11 Million | -3.44 Million | -4.59 Million | -811 Thousand | -317 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 32.95 Million | 38.72 Million | 860 Thousand | 201.96 Million | 199.89 Million | 854 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 32.95 Million | 38.72 Million | 860 Thousand | 201.96 Million | 199.89 Million | 854 Thousand |
| Other Financing Activities | 30.24 Million | 38.72 Million | -225 Thousand | -355 Thousand | 199.89 Million | 854 Thousand |
| Accounts receivables | 1000.00 | -610 Thousand | -447 Thousand | -521 Thousand | -4000.00 | -23 Thousand |
| Accounts payables | 17.42 Million | 4.05 Million | 2.91 Million | 2.1 Million | -1.59 Million | -1.54 Million |
| Inventory | - | - | 11.11 Million | - | -9.25 Million | -1.85 Million |
| Other working capital | 18.06 Million | 3.75 Million | 25.89 Million | 13.76 Million | -119 Thousand | -30 Thousand |
| Cash at beginning of period | 252.48 Million | 277.92 Million | 337.32 Million | 273.86 Million | 192.49 Million | 234.25 Million |
| Cash at end of period | 226.86 Million | 252.48 Million | 277.92 Million | 277.92 Million | 337.32 Million | 192.49 Million |
| Capital Expenditure | -1.21 Million | -1.11 Million | -3.44 Million | -4.59 Million | -811 Thousand | -317 Thousand |
| Effect of forex changes on cash | - | - | 102.46 Million | - | -144.53 Million | 42.06 Million |
| Net cash flow / Change in cash | -25.62 Million | -25.44 Million | -59.4 Million | 4.05 Million | 144.83 Million | -41.76 Million |
| Free Cash Flow | -58.57 Million | -64.16 Million | -60.26 Million | -197.9 Million | -55.05 Million | -42.61 Million |
CSKL
LLOYDSENGG
281740
MMTC
002890
ANX